摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(Propan-2-yloxy)butanoic acid | 1017026-56-0

中文名称
——
中文别名
——
英文名称
4-(Propan-2-yloxy)butanoic acid
英文别名
4-propan-2-yloxybutanoic acid
4-(Propan-2-yloxy)butanoic acid化学式
CAS
1017026-56-0
化学式
C7H14O3
mdl
MFCD09944713
分子量
146.18
InChiKey
QEILUWNNSOGIFP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    238.3±23.0 °C(Predicted)
  • 密度:
    1.005±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    10
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.857
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] SUBSTITUTED OXOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS
    申请人:BAYER AG
    公开号:WO2020127508A1
    公开(公告)日:2020-06-25
    The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
    这项发明涉及替代氧吡啶衍生物及其制备方法,以及它们用于制备治疗和/或预防疾病的药物,特别是血管疾病,最好是血栓性或血栓栓塞性疾病和/或血栓性或血栓栓塞性并发症。
  • Water-Soluble and Water-Insoluble, Ring Opening Metathesis Polymerization Products, Monomers and Related Methods
    申请人:Tew Gregory N.
    公开号:US20090082524A1
    公开(公告)日:2009-03-26
    The invention provides certain novel water-soluble and water-insoluble monomers for ring opening metathesis polymerization and novel polymers, compositions and products, and related methods thereof.
    这项发明提供了用于环氧烯烃开环重聚合的某些新型溶性和不溶性单体,以及新型聚合物、组合物和产品,以及相关方法。
  • Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto
    申请人:Zhu Yun-Fei
    公开号:US20080262005A1
    公开(公告)日:2008-10-23
    Compounds having utility as GnRH receptor antagonists and for treatment of a variety of sex-hormone related conditions in both men and women. Such compounds have the following structure (I): (I) wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 , R 7 , n and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of structure (I) in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    具有GnRH受体拮抗剂实用性的化合物,用于治疗男性和女性的多种性激素相关疾病。这些化合物具有以下结构(I):(I)其中R1a,R1b,R1c,R2a,R2b,R3,R4,R5,R6,R7,n和X如此定义,包括立体异构体,前药和其药物学上可接受的盐。还披露了含有结构(I)的化合物和药学上可接受的载体的组合物,以及与使用其在需要拮抗促性腺激素释放激素的受试者相关的方法。
  • NOVEL CASE OF RENIN INHIBITORS
    申请人:Wu Tom Yao-Hsiang
    公开号:US20100120859A1
    公开(公告)日:2010-05-13
    The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.
    本发明涉及基于哌啶的肾素抑制剂化合物,其具有羧酸盐或羧酸末端基团,并且它们在治疗心血管事件和肾功能不全方面的使用。
  • TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:EP1979331B1
    公开(公告)日:2012-03-07
查看更多